Eisai Stock Quote, Financial Performance, and Strength

Eisai has consistently demonstrated strong financial performance, with a market capitalization of over $20 billion as of 2022.

The company's revenue has grown steadily over the years, reaching $10.6 billion in 2020.

Eisai's financial strength is evident in its ability to invest heavily in research and development, allocating over 20% of its revenue to R&D in 2020.

This commitment to innovation has led to the development of several successful drugs, including LENVIMA and HALAVEN.

Eisai's financial health is a crucial aspect to consider when evaluating the stock. The company's cash-to-debt ratio is 1.47, indicating a relatively strong financial position.

One of the key metrics to look at is the debt-to-equity ratio, which is 0.22. This suggests that Eisai has a manageable level of debt compared to its equity.

The interest coverage ratio is a healthy 17.18, indicating that the company has sufficient cash flow to meet its interest payments. The Piotroski F-Score is 3/9, which is a neutral indicator of the company's financial health.

Eisai's Altman Z-Score is 3.21, which falls into the "Distress" category, indicating that the company is at risk of bankruptcy. However, it's essential to consider this metric in conjunction with other financial indicators.

Here are some key financial data points for Eisai:

Eisai's equity ratio is 64.50%, indicating that the company has a relatively high level of equity compared to its assets. The debt ratio is 35.50%, which is a manageable level of debt.

The company's income statements show a steady increase in sales over the years, with a slight decline in 2024. The operating income has also shown a steady increase, with a significant jump in 2020. However, the income after tax has shown a decline in 2024.

Overall, Eisai's financial information suggests that the company has a relatively strong financial position, but there are some areas of concern, such as the Altman Z-Score and the decline in income after tax.

Eisai is a Japanese pharmaceutical company with a market capitalization of over $70 billion.

The company was founded in 1948 by Akira Higuchi and Takashi Takeuchi in Tokyo, Japan.

Eisai has a diverse portfolio of products, including oncology, neurology, and infectious disease treatments.

Their flagship product is Lenvima, a cancer treatment that has received FDA approval in the US.

Eisai's revenue has consistently grown over the years, with a net sales increase of 15% in 2020.

The company has a strong presence in the global market, with operations in over 30 countries.

Eisai's stock is listed on the Tokyo Stock Exchange and the New York Stock Exchange.

Over the past year, Eisai stock has seen a significant decline in performance, with a return of -34.55%.

Looking at the shorter-term performance, the stock has also struggled, with a 7.23% decline over the past three months.

In contrast, the stock has shown some promise in the shorter-term, with a 12.55% increase over the past week and an 18.56% gain over the past month.

Here's a breakdown of the stock's performance over different time periods:

The Eisai stock price is 31.500 USD today. This is a significant factor to consider when evaluating the company's performance.

Eisai's stock price has fluctuated over time, but as of today, it stands at 31.500 USD.

ESALF's performance has shown some significant fluctuations over time.

One week into the investment, ESALF saw a 12.55% increase in value.

However, this growth didn't sustain itself, as the stock price dropped by 18.56% over the course of a month.

Looking at a slightly longer time frame, ESALF's performance was actually in the red, with a 3-month decline of 7.23%.

But the biggest drop came over the course of a year, with a staggering 34.55% decrease in value.

Here's a quick summary of ESALF's performance over different time periods:

This data suggests that ESALF's stock price may not be as stable as some investors might hope.

Eisai's financial metrics paint a picture of a company with a solid foundation. The cash-to-debt ratio is 1.47, indicating that the company has a manageable level of debt.

The equity-to-asset ratio is 0.62, which is relatively low, suggesting that the company may be over-leveraged. However, the debt-to-equity ratio of 0.22 indicates that the company's debt is manageable compared to its equity.

The interest coverage ratio is 17.18, which is very high, indicating that the company has a strong ability to pay its interest expenses. The Piotroski F-Score is 3, which is a mediocre score, indicating some concerns about the company's financial health.

Here are some key financial metrics for Eisai:

The Altman Z-Score is 3.21, indicating that the company is in a "Grey" zone, suggesting some financial distress. However, the Beneish M-Score is -2.5, indicating that the company is not a manipulator.

Financial Strength is a crucial aspect of any company's overall health. A company's financial strength is often measured by its ability to pay off debt, generate profits, and maintain a stable financial position.

One key indicator of financial strength is the Cash-To-Debt ratio, which measures a company's ability to pay off its debts using its cash reserves. In the example provided, the company's Cash-To-Debt ratio is 1.47, indicating a strong ability to pay off debts.

A company's Equity-to-Asset ratio is another important indicator of financial strength. This ratio measures the proportion of a company's assets that are financed by equity rather than debt. In the example, the company's Equity-to-Asset ratio is 0.62, which suggests that the company has a moderate level of equity financing.

Debt-to-Equity is also an important metric, as it measures the proportion of a company's assets that are financed by debt rather than equity. With a Debt-to-Equity ratio of 0.22, this company has a relatively low level of debt financing.

The Debt-to-EBITDA ratio is another key indicator of financial strength, as it measures a company's ability to pay off its debts using its earnings before interest, taxes, depreciation, and amortization (EBITDA). In the example, the company's Debt-to-EBITDA ratio is 1.82, which suggests a moderate level of debt financing.

Interest Coverage is another important metric, as it measures a company's ability to pay off its interest expenses using its earnings. With an Interest Coverage ratio of 17.18, this company has a strong ability to pay off its interest expenses.

Finally, the Piotroski F-Score is a measure of a company's financial health, with higher scores indicating better financial health. In the example, the company's Piotroski F-Score is 3/9, which suggests a relatively weak financial health.

Here's a summary of the company's financial strength metrics:

The company's financial strength metrics suggest a mixed picture, with some indicators suggesting a strong ability to pay off debts and others indicating a relatively weak financial health.

The valuation of a company can be a complex topic, but let's break it down to the basics.

The price-to-earnings (P/E) ratio is a widely used metric to evaluate a company's stock performance. In the case of ESALF, the current P/E ratio is 33.067.

A high P/E ratio can indicate that investors are expecting high growth from the company, while a low P/E ratio may suggest that the company's growth prospects are limited.

The P/E ratio without extraordinary items is 40.168, which is slightly higher than the current P/E ratio.

Here are some key valuation metrics for ESALF:

A low price-to-sales ratio, such as 2.296 for ESALF, can indicate that the company's stock is undervalued compared to its sales performance.